钙激活钾通道 K1.1 作为克服三维肉瘤球体模型中化疗耐药性的治疗靶点。
Ca -activated K channel K 1.1 as a therapeutic target to overcome chemoresistance in three-dimensional sarcoma spheroid models.
机构信息
Department of Pharmacology, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan.
Department of Complex Molecular Chemistry, The Institute of Scientific and Industrial Research, Osaka University, Osaka, Japan.
出版信息
Cancer Sci. 2021 Sep;112(9):3769-3783. doi: 10.1111/cas.15046. Epub 2021 Jul 16.
The large-conductance Ca -activated K channel K 1.1 plays a pivotal role in tumor development and progression in several solid cancers. The three-dimensional (3D) in vitro cell culture system is a powerful tool for cancer spheroid formation, and mimics in vivo solid tumor resistance to chemotherapy in the tumor microenvironment (TME). K 1.1 is functionally expressed in osteosarcoma and chondrosarcoma cell lines. K 1.1 activator-induced hyperpolarizing responses were significantly larger in human osteosarcoma MG-63 cells isolated from 3D spheroid models compared with in those from adherent 2D monolayer cells. The present study investigated the mechanisms underlying the upregulation of K 1.1 and its role in chemoresistance using a 3D spheroid model. K 1.1 protein expression levels were significantly elevated in the lipid-raft-enriched compartments of MG-63 spheroids without changes in its transcriptional level. 3D spheroid formation downregulated the expression of the ubiquitin E3 ligase FBXW7, which is an essential contributor to K 1.1 protein degradation in breast cancer. The siRNA-mediated inhibition of FBXW7 in MG-63 cells from 2D monolayers upregulated K 1.1 protein expression. Furthermore, a treatment with a potent and selective K 1.1 inhibitor overcame the chemoresistance of the MG-63 and human chondrosarcoma SW-1353 spheroid models to paclitaxel, doxorubicin, and cisplatin. Among several multidrug resistance ATP-binding cassette transporters, the expression of the multidrug resistance-associated protein MRP1 was upregulated in both spheroids and restored by the inhibition of K 1.1. Therefore, the pharmacological inhibition of K 1.1 may be an attractive new strategy for acquiring resistance to chemotherapeutic drugs in the TME of K 1.1-positive sarcomas.
大电导钙激活钾通道 K 1.1 在几种实体瘤的肿瘤发生和进展中发挥关键作用。三维(3D)体外细胞培养系统是形成肿瘤球体的有力工具,可模拟肿瘤微环境(TME)中体内实体肿瘤对化疗的耐药性。K 1.1 在骨肉瘤和软骨肉瘤细胞系中功能性表达。与来自贴壁 2D 单层细胞的细胞相比,从 3D 球体模型分离的人骨肉瘤 MG-63 细胞中 K 1.1 激活剂诱导的超极化反应明显更大。本研究使用 3D 球体模型研究了 K 1.1 上调的机制及其在化疗耐药中的作用。K 1.1 蛋白表达水平在 MG-63 球体富含脂筏的隔室中显著升高,而其转录水平没有变化。3D 球体形成下调了泛素 E3 连接酶 FBXW7 的表达,FBXW7 是乳腺癌中 K 1.1 蛋白降解的重要贡献者。在来自 2D 单层的 MG-63 细胞中用 siRNA 抑制 FBXW7 可上调 K 1.1 蛋白表达。此外,用一种有效的、选择性的 K 1.1 抑制剂处理可克服 MG-63 和人软骨肉瘤 SW-1353 球体模型对紫杉醇、多柔比星和顺铂的化疗耐药性。在几种多药耐药 ATP 结合盒转运蛋白中,多药耐药相关蛋白 MRP1 的表达在球体中均上调,并通过抑制 K 1.1 恢复。因此,药理学抑制 K 1.1 可能是一种有吸引力的新策略,可用于获得 K 1.1 阳性肉瘤 TME 中化疗药物的耐药性。